

.

**Investor Presentation** 

May 7, 2024

#### **Cautionary notices**

This presentation contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, products and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this presentation to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

#### No offer to sell or buy

This presentation does not constitute an offer to sell or a solicitation of an offer to buy any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

#### **Other material information**

This presentation does not contain all material information about SOPHiA GENETICS SA and its subsidiaries. No representations or warranties (expressed or implied) are made regarding the completeness of the information contained in this presentation. Refer to our Securities and Exchange Commission filings for additional information about us.

#### Market and industry data

This presentation contains industry, market and competitive position data that are based on general and industry publications, surveys and studies conducted by third parties, some of which may not be publicly available, and our own internal estimates and research. Third-party publications, surveys and studies generally state that they have obtained information from sources believed to be reliable, but do not guarantee the accuracy and completeness of such information. While we are not aware of any misstatements regarding the industry, market and competitive position data presented herein, these data involve a number of assumptions and limitations and contain projections and estimates of the future performance of the industries in which we operate that are subject to a high degree of uncertainty

#### **Research use only**

SOPHIA GENETICS products are for Research Use Only and not for use in diagnostic procedures, unless specified otherwise. The information included in this presentation is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence.



#### Contents

- SOPHiA GENETICS' mission to democratize data-driven medicine
- SOPHiA DDM<sup>TM</sup>: The Platform at the heart of our mission
- Q1 2024 Performance update



#### **SOPHiA GENETICS at-a-glance**



We are a category defining software company on a mission to

**Democratize Data-Driven Medicine Together** 



#### Explosion of healthcare data


Advancements in cloud-based computing




Developments in artificial intelligence

The age of data-driven medicine SOPHiA DDM<sup>™</sup>

## For decades, health data has been produced in silos




SOPHiA GENETICS was founded to break data silos and expand access to data-driven medicine...



...by using AI to deliver world-class care to patients across the globe.

## SOPHiA DDM<sup>™</sup> is a decentralized analytics platform which computes complex data and provides insights to Clinical and BioPharma customers



#### We are targeting a sizeable addressable market

#### **Clinical market**

Generating insights from multimodal data to help Clinicians with screening, early detection, diagnosis, therapy selection, and monitoring

\$25**B** 

10

#### **BioPharma market**

Generating insights from multimodal data to help BioPharma companies with drug discovery, development, and deployment

\$15**B** 

SOPHIA DDM<sup>™</sup>


The decentralized, cloud-based analytics platform at the center of it all





#### The SOPHIA DDM<sup>™</sup> Platform uniquely serves this market







#### Our vast, global network of healthcare institutions share insights and contribute to a collective intelligence HENRY Ŵ IEO Istituto Europeo Pacologia FORD **Carbone Cancer Center** HEALTH UNIVERSITY OF WISCONSIN DOL OF MEDICINE AND PUBLIC HEALT FN MOTOL CLIENT NETWORK<sup>1</sup> 770+ connected ~70 GUSTAVE/ ROUSSY-Dana-Farber ROSWELL PARK. healthcare institutions countries MAYO CLINIC MOFFITT DCDD Memorial Sloan Kettering ወወ הפרכז הרפואי שערי צדק SHAARE ZEDEK Ù SYNERGY STUDIO UMass Memorial Health AMADOR


#### Contents

- SOPHiA GENETICS' mission to democratize data-driven medicine
- SOPHiA DDM<sup>TM</sup>: The Platform at the heart of our mission
- Q1 2024 Performance update



Industry-leading multimodal capabilities driven by AI makes SOPHiA DDM<sup>™</sup> the platform of choice for actionable patient insights


#### SOPHIA DDM<sup>™</sup>





## SOPHiA DDM<sup>™</sup> enables Clinical customers to become beacons of precision medicine

ILLUSTRATIVE GENOMIC OFFERING




customers per analysis run on SOPHiA DDM<sup>TM</sup>

## Customers choose SOPHiA DDM<sup>™</sup> for its accuracy, expedited turnaround time, decentralized approach, and cost savings






## Comprehensive portfolio of SOPHiA DDM<sup>™</sup> applications serves customers across their precision medicine needs






#### Analysis volume on SOPHiA DDM<sup>™</sup> is growing rapidly across all applications



© SOPHiA GENETICS 2024 (1) Year-over-year analysis volume as of December 31, 2023. Analysis volume growth is presented excluding COVID-related volumes.

#### Data processed on SOPHiA DDM<sup>™</sup> has exploded over the years






SOPHiA DDM<sup>™</sup> leverages the advanced AI powering the platform as well as the real-time, real-world data computed daily to deliver valuable insights to our BioPharma partners across the drug continuum

**DEPLOYING** SOPHiA DDM<sup>™</sup> in the clinical market creates a flywheel effect...

... by collecting data and insights which enable BioPharma customers to **DISCOVER** and **DEVELOP** better treatments as well as **DEPLOY** their treatments to new populations






#### Contents

- SOPHiA GENETICS' mission to democratize data-driven medicine
- SOPHiA DDMTM: The Platform at the heart of our mission
- Q1 2024 Performance update



#### Q1 2024 Highlights

#### Consistent Operational Execution; Robust New Business Momentum; Guidance Reaffirmed



#### Expanding usage of SOPHiA DDM<sup>™</sup> worldwide

- Q1 analysis volume was ~84,000
- 463 core genomics customers as of Q1 2024, up from 437 in Q1 2023
- Launched new Liquid Biopsy application, MSK-ACCESS<sup>®</sup> powered with SOPHiA DDM<sup>™</sup>
- Signed an impressive 9 customers pre-launch; Indicative of significant market demand

#### Accelerating adoption of SOPHiA DDM<sup>™</sup> by landing new customers

- Landed 27 new customers in Q1 2024, adding to the 35 new customers signed in Q4
- Continued momentum in U.S.; 34% YoY analysis volume growth; 27% revenue growth
- Added 3 new countries with the signing of customers in Romania, Norway, and Nigeria
- Signed our first customer in Africa as part of our collaboration with MSK and AstraZeneca
- Built traction with the U.K.'s National Health Service ("NHS") with new signings

#### Maintaining an obsession on operational excellence

- Improved adjusted operating loss 13% year-over-year in Q1 2024
- Maintained adjusted gross margin above 70%
- Reaffirmed commitment to achieve adjusted operating profitability<sup>1</sup> in next 2+ years

#### Strengthening our capital position to support future growth initiatives

## **PERCEPTIVE** ADVISORS

#### New financing agreement:

- New, five-year senior secured credit facility with Perceptive Advisors
- Provides access of up to \$50 million in debt financing
- Financing consists of an initial tranche of \$15 million, and an additional tranche of \$35 million available for draw through March 2026



#### **Growth drivers for 2024**

Potential catalysts for growth in 2024

**Liquid Biopsy:** Deploy new Liquid Biopsy offering worldwide with the help of BioPharma partners

Solid tumors: Capitalize on the demand of increasingly complex signatures, including HRD




U.S. market: Build off strong momentum and marquee names from 2023

**New offerings:** Launch new applications and features in Solid Tumors, HemOnc, Whole Genome Sequencing, and Pharmacogenomics as well as a full platform modernization and upgraded multimodal capabilities

**BioPharma:** Continue partnering to deploy SOPHiA DDM<sup>™</sup> and unlock multimodal data & analytics



#### Official launch of our new Liquid Biopsy application in April



#### Momentum continues in the U.S. with 34% analysis volume growth

#### Q1 2024 Highlights







#### 2024 annual guidance reaffirmed

Category	FY 2023 results	FY 2024 guide	YoY improvement	Key drivers			
				<ul> <li>Focus on accelerating 27 new logos from Q1 and 35 new logos from Q4 into routine usage faster</li> </ul>			
Revenue	\$62.4M	\$78M - \$81M	25% – 30% growth	<ul> <li>Capitalize on growing demand for Liquid Biopsy application, MSK- ACCESS<sup>®</sup> powered with SOPHiA DDM<sup>™</sup></li> </ul>			
				<ul> <li>Maintain strong performance of world-class Solid Tumor applications such as HRD</li> </ul>			
				• Build off significant momentum in the <b>U.S.</b> with recent wins			
Adjusted gross margin	72.2%	72.5% - 72.7%	50bps improvement	<ul> <li>Benefit from economies of scale for cloud-based compute and storage costs as well as favorable price capture during back-half of 2024</li> </ul>			
Adjusted	¢ΓΓ ΟΜ		11% - 19%	<ul> <li>Continue obsession with operational excellence to continue delivering improvements</li> </ul>			
operating loss	\$55.9M	\$45M - \$50M	improvement	improvement	improvement	improvement	<ul> <li>Take advantage of actions from second half of 2023 and focus on continue lowering professional service fees and optimizing public company costs</li> </ul>

**Note:** Other than with respect to revenue, the Company only provides guidance on a non-IFRS basis. The Company does not provide a reconciliation of forward-looking adjusted gross margin (non-IFRS measure) to gross margin (the most comparable IFRS financial measure), due to the inherent difficulty in forecasting and quantifying amortization of capitalized research & development expenses that are necessary for such reconciliation. In addition, the Company does not provide a reconciliation of forward-looking adjusted operating loss (non-IFRS measure) to operating loss (the most comparable IFRS financial measure), due to the inherent difficulty in forecasting amortization of capitalized research & development expenses and intervent difficulty in forecasting and quantifying amortization of capitalized research & development expenses and intervent difficulty in forecasting and quantifying amortization of capitalized research & development expenses and intervent difficulty in forecasting and quantifying amortization of capitalized research & development expenses and intervent difficulty in forecasting and quantifying amortization of capitalized research & development expenses and intervent difficulty in forecasting and quantifying amortization of capitalized research & development expenses and intervent difficulty in forecasting and quantifying amortization of capitalized research & development expenses and intervent difficulty in forecasting and quantifying amortization of pensions paid in excess of actual contributions, that are necessary for such reconciliation.

#### Path to profitability in the next 2+ years

# 2021 2022 2023 2024 2025

Near term path to profitability<sup>(1)</sup>

#### Another quarter of consistent bottom-line improvement in Q1 2024



•••

(1) Profitability is defined as positive adjusted operating income.
 (2) IFRS gross margin in Q1 2024 of 65.9%.
 (3) IFRS operating margin improvement in Q1 2024 of 3%
 © SOPHiA GENETICS 2024
 (4) Cash burn represents the change in cash and cash equivalents and term deposits during the year.

#### **Investment highlights**

	Sizable addressable market	~\$40B market opportunity <sup>(1)</sup>	
	Market-leading technology	\$400M+663invested sincescientificinceptionpublications	Q1 2024 highlights
<b>O</b>	Customers love SOPHiA DDM™	FY 2023 highlights Figures as of Dec 31, 202375~4%+87NPS score among SOPHiA DDM™ users <sup>(2)</sup> annualized revenue churnnew customers signed in 2023	+27 new customers signed in Q1 2024
	Highly recurring business	130%27%317K+464Net Dollar Retention in 2023analysis volume growth in 2023analysis volume in 2023(3)core genomic customers as of Q	<b>84K+</b> analysis volume in 1 Q1 2024 <sup>(3)</sup>
	Attractive operating model	32%72%36%\$104M2+year-over-year revenue growth in 2023adjusted gross margin in FY 2023cash burn improvement in 2023(5)cash balance as of Q1 2024year path to profitability	

(1) Includes our estimated addressable market for 2024. These estimates are primarily based on epidemiological data, including incidence and prevalence estimates of addressable populations for each application, as well as a range of price assumptions for our products taking into account differences in panel sizes

(2) NPS Score reflects survey results users of SOPHiA DDM<sup>TM</sup>'s core genomic module (i.e., SOPHiA DDM for Genomics) only and excludes survey results from users of add-on modules such as Alamut. (3) Platform analysis volume for FY 2023, including COVID-related volume.

(4) Constant currency revenue growth excluding COVID.

© SOPHIA GENETICS 2024 (5) Cash burn represents the change in cash and cash equivalents and term deposits during the quarter.

## SOPHIA GENETICS<sup>™</sup>

Democratizing Data-Driven Medicine, Together

#### **Financial overview**

(\$ in millions, except for margin data)

Q4 2024 P&L	Q1 2024	Q1 2023	Change Y/Y
Total revenues	\$15.8	\$14.0	13%
Adjusted gross margin %	70.5%	72.5%	(196bps)
Adjusted operating loss	(\$14.1)	(\$16.2)	(13%)
Cash burn	(\$19.5) <sup>1</sup>	(\$16.8)	(16.3%)
Balance sheet	March 31, 2024	March 31, 2023	Change Y/Y
Cash & cash equivalents	\$103.7	\$161.9	(\$58.2)



#### **Reconciliation of IFRS Financials to Adjusted Financials**

	2023					2024				
(Amounts in USD Thousands)	Q1	Q2	Q3	Q4	FY	Q1	Q2	Q3	Q4	FY
IFRS Revenue	\$13,966	\$15,054	\$16,303	\$17,048	\$62,371	\$15,779				
Gross Profit	\$9,694	\$10,047	\$11,273	11,898	\$42,913	\$10,405				
Gross Margin	69%	67%	69%	70%	69%	66%				
Amortization of Capitalized Development Expenses $^{(1)}$	432	496	552	619	2,099	727				
Adjusted Gross Profit	\$10,126	\$10,543	\$11,825	\$12,517	\$45,012	11,132				
Adjusted Gross Margin	73%	70%	73%	73%	72%	70.5%				

	2023					2024				
(Amounts in USD Thousands)	Q1	Q2	Q3	Q4	FY	Q1	Q2	Q3	Q4	FY
IFRS Revenue	\$13,966	\$15,054	\$16,303	\$17,048	\$62,371	\$15,779				

Operating Profit / (Loss)	(\$19,287)	(\$20,047)	(\$16,544)	(\$18,946)	(\$74,826)	\$(18,757)		
Operating Margin	(138%)	(133%)	(101%)	(111%)	(120%)	(119%)		
Amortization of Capitalized Development Expenses <sup>(1)</sup>	432	496	552	619	2,099	727		
Share-Based Compensation Expense <sup>(2)</sup>	2,430	4,676	3,930	4,211	15,247	3,714		
Amortization of Intangible Expense <sup>(3)</sup>	173	179	184	193	729	174		
Non-Cash Pension Expense <sup>(4)</sup>	78	84	69	(625)	(394)	77		
Cost Associated with Restructuring <sup>(5)</sup>				1,232	1,232			
Adjusted Operating Profit / (Loss)	(\$16,174)	(\$14,612)	(\$11,809)	(\$13,316)	(\$55,913)	\$(14,065)		
Adjusted Operating Margin	(116%)	(97%)	(72%)	(78%)	(90%)	(89%)		

#### Notes to the Reconciliation of IFRS to Adjusted Financial Measures Tables

- (1) Amortization of capitalized research and development expenses consists of software development costs amortized using the straight-line method over an estimated life of five years. These expenses do not have a cash impact but remain a recurring expense generated over the course of our research and development initiatives.
- (2) Amortization of intangible assets consists of costs related to intangible assets amortized over the course of their useful lives. These expenses do not have a cash impact, but we could continue to generate such expenses through future capital investments.
- (3) Share-based compensation expense represents the cost of equity awards issued to our directors, officers, and employees. The fair value of awards is computed at the time the award is granted and is recognized over the vesting period of the award by a charge to the income statement and a corresponding increase in other reserves within equity. These expenses do not have a cash impact but remain a recurring expense for our business and represent an important part of our overall compensation strategy
- (4) Non-cash pension expense consists of the amount recognized in excess of actual contributions made to our defined pension plans to match actuarial expenses calculated for IFRS purposes. The difference represents a non-cash expense but remains a recurring expense for our business as we continue to make contributions to our plans for the foreseeable future.
- (5) Costs associated with restructuring consists of compensation paid to employees during their garden leave period, severance, and any other amounts legally owed to the employees resulting from their termination as part of a planned workforce reduction, which we undertook to optimize our operations. Additionally, it includes any legal fees incurred as part of the restructuring process. While such actions are not planned going forward as part of our regular operations, we expect such expenses could still be incurred from time to time based on corporate needs.

#### Reconciliation of IFRS Revenue Growth to Constant Current Revenue Growth Excluding COVID-19-Related Revenue

(Amounts in USD Thousands)	Q1 2023	FY 2023	Q1 2024	Y-o-Y Growth
IFRS Revenue	\$13,991	\$62,371	\$15,798	13%
Current Period Constant Currency Impact <sup>(1)</sup>	_	_	(184)	
Constant Currency Revenue	\$13,991	\$62,371	\$15,614	12%
COVID-19 Related Revenue Constant Currency Impact on COVID-19-Related Revenue	(125)	(319)	(35) 2	
Constant Currency Revenue Excluding COVID-19-Related Revenue	\$13,866	\$62,052	\$15,580	12%

#### Presentation of Constant Currency Revenue and Excluding COVID-19-Related Revenue

SOPHiA GENETICS operates internationally, and its revenues are generated primarily in the U.S. dollar, the euro and Swiss franc and, to a lesser extent, British pound, Australian dollar, Brazilian real, Turkish lira and Canadian dollar depending on the company's customers' geographic locations. Changes in revenue include the impact of changes in foreign currency exchange rates. We present the non-IFRS financial measure "constant currency revenue" (or similar terms such as constant currency revenue growth) to show changes in revenue without giving effect to period-to-period currency fluctuations. Under IFRS, revenues received in local (non-U.S. dollar) currencies are translated into U.S. dollars at the average monthly exchange rate for the month in which the transaction occurred. When the company uses the term "constant currency", it means that it has translated local currency revenues for the current reporting period into U.S. dollars using the same average foreign currency exchange rates for the conversion of revenues into U.S. dollars that we used to translate local currency revenues for the company then calculates the difference between the IFRS revenue and the constant currency revenue to yield the "constant currency impact" for the current period.

The company's management and board of directors use constant currency revenue growth to evaluate growth and generate future operating plans. The exclusion of the impact of exchange rate fluctuations provides comparability across reporting periods and reflects the effects of customer acquisition efforts and land-and-expand strategy. Accordingly, it believes that this non-IFRS measure provides useful information to investors and others in understanding and evaluating revenue growth in the same manner as the management and board of directors. However, this non-IFRS measure has limitations, particularly as the exchange rate effects that are eliminated could constitute a significant element of its revenue and could significantly impact performance and prospects. Because of these limitations, you should consider this non-IFRS measure alongside other financial performance measures, including revenue growth presented in accordance with IFRS and other IFRS results.

In addition to constant currency revenue, the company presents constant currency revenue excluding COVID-19-related revenue to further remove the effects of revenues that are derived from sales of COVID-19-related offerings, including a NGS assay for COVID-19 that leverages the SOPHiA DDMTM Platform and related products and solutions analytical capabilities and COVID-19 bundled access products. SOPHiA GENETICS do not believe that these revenues reflect its core business of commercializing its platform because the company's COVID-19 solution was offered to address specific market demand by its customers for analytical capabilities to assist with their testing operations. The company does not anticipate additional development of its COVID-19-related solution as the pandemic transitions into a more endemic phase and as customer demand continues to decline. Further, COVID-19-related revenues did not constitute, and the company does not expect COVID-19-related revenues to constitute in the future, a significant part of its revenue. Accordingly, the company believes that this non-IFRS measure provides useful information to investors and others in understanding and evaluating its revenue growth. However, this non-IFRS measure has limitations, including that COVID-19-related revenues contributed to the company's cash position, and other companies may define COVID-19-related revenues differently. Because of these limitations, you should consider this non-IFRS measure alongside other financial performance measures, including revenue and revenue growth presented in accordance with IFRS and other IFRS results.